Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Purple Biotech (NASDAQ/TASE: PPBT) received a Nasdaq notice on Oct 16, 2025 that its American Depositary Shares closed below the required $1.00 minimum for 30 consecutive trading days. Under Nasdaq Listing Rule 5810(c)(3)(A) the company has a 180‑day cure period until April 14, 2026 to regain compliance by achieving a closing bid ≥ $1.00 for ten consecutive business days. The notice does not affect the current Nasdaq listing or trading of ADSs, nor its Tel Aviv listing. If noncompliant by April 14, 2026, Purple Biotech may be eligible for a second 180‑day period if it meets market‑value and other listing standards, or face delisting and the option to appeal. The company said it will monitor the ADS price and may consider options such as changing the ADS-to-ordinary share ratio to regain compliance.
Purple Biotech (NASDAQ/TASE: PPBT) has received an intention to grant from the European Patent Office for a patent application covering NT219 combinations with immunotherapies and MEK inhibitors. The patent (Application No. 20168234.1) will protect combinations of NT219 with various immunotherapies including anti-PD-1, PD-L1, CTLA-4, and CD20 antibodies, designed to enhance treatment of resistant cancers.
The company is currently conducting a Phase 2 study evaluating NT219 in combination with either pembrolizumab or cetuximab for squamous cell carcinoma of the head and neck (SCCHN). Preclinical studies have demonstrated synergistic activity of NT219 with immunotherapy in suppressing refractory tumors across multiple indications. The patent protection extends through 2036.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on oncology therapeutics, has closed its previously announced public offering. The offering includes 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, with each ADS representing 200 ordinary shares, at $1.00 per share.
The offering also includes short-term warrants to purchase up to 11,999,998 ADSs at an exercise price of $1.00 per ADS, exercisable immediately and expiring in 24 months. The initial gross proceeds total $6 million, with potential additional proceeds of $12 million if all warrants are exercised. H.C. Wainwright & Co. served as the exclusive placement agent.
The company plans to use the proceeds for developing its oncology therapeutic candidates and general working capital purposes.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor treatment, has announced the pricing of a $6 million public offering with potential additional proceeds of up to $12 million through warrant exercises.
The offering consists of 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, priced at $1.00 per share. Each ADS represents 200 ordinary shares. Additionally, short-term warrants to purchase up to 11,999,998 ADSs at $1.00 per ADS will be issued, exercisable immediately and expiring in 24 months. The offering is expected to close around September 5, 2025.
H.C. Wainwright & Co. serves as the exclusive placement agent. Proceeds will fund oncology therapeutic candidates development and general corporate purposes.
Purple Biotech (NASDAQ/TASE: PPBT) has announced promising new data for its CAPTN-3 tri-specific antibody IM1240 in collaboration with Mount Sinai. The research, led by Dr. Amir Horowitz, demonstrated successful tumor cell death in treatment-resistant head and neck cancer biopsies.
Key findings show synergistic effects between NK and T cell engager arms of IM1240, and analysis of 26,000 human transcriptomes validates the antibody's design targeting 5T4 and NKG2A. The company plans to submit an IND application in 2026 for first-in-human clinical trials.
The research spans multiple resistant cancers including NSCLC, HNSCC, and bladder cancer. IM1240's unique design offers potentially safer checkpoint inhibition compared to existing therapies, particularly through its selective NKG2A targeting.
Purple Biotech (NASDAQ/TASE: PPBT) has announced the development of IM1305, its second CAPTN-3 tri-specific antibody targeting TROP2. The novel antibody combines a masked anti-CD3 arm, an anti-NKG2A arm, and an anti-TROP2 arm to target solid tumors.
Preclinical results show sustained tumor regression in human triple negative breast cancer (TNBC) mouse models, with significant cell death induction across multiple tumor types at low doses. The antibody's unique design includes a cleavable cap that activates specifically in the tumor microenvironment, potentially reducing off-target effects.
TROP2, the target protein, is widely expressed in major solid tumors including breast, lung, gastrointestinal, and ovarian cancers. The company plans to leverage its platform technology to accelerate development and explore partnering opportunities.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO Gil Efron will participate in a fireside chat on September 10, 2025, at 11:30 AM ET. The company will also be available for one-on-one investor meetings through the conference portal.
Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2025 financial results and significant clinical progress across its pipeline. The company highlighted positive data from its CAPTN-3 tri-specific antibody platform at EACR 2025, with plans to submit an IND for IM1240 in 2026.
Key clinical achievements include statistically significant Phase 2 results for CM24 in pancreatic cancer, showing up to 78% reduction in death risk and 37.5% ORR in biomarker-selected patients. The company also initiated a Phase 2 study of NT219 in head and neck cancer.
Financial highlights include reduced R&D expenses to $0.6M (down 76.9% YoY), operating loss of $1.2M (down 64.3% YoY), and cash position of $5.6M, providing runway into Q3 2026.
Purple Biotech (NASDAQ/TASE: PPBT) CEO Gil Efron shared significant progress in their clinical pipeline during H1 2025. The company's lead candidate CM24 showed promising Phase 2 results in pancreatic cancer (PDAC), with notably higher objective response rates in biomarker-enriched subgroups (37.5% vs 0% control).
Key developments include positive data from the CAPTN-3 platform presented at EACR 2025, featuring novel capping technology, and advancement of NT219 into Phase 2 combination studies. The company plans to initiate a biomarker-driven Phase 2b study for CM24 and expects to submit an IND for CAPTN-3's first candidate in 2026.
Purple Biotech maintains a cash runway extending into mid-2026, though additional funding will be required for future clinical studies.